Showing 141-150 of 404 results for "".
- BTL Suit Alleges False Advertising by Allerganhttps://modernaesthetics.com/news/btl-suit-alleges-false-advertising-by-allergan-1/2472885/In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges that Allergan's marketing, sales materials, and soci
- Cynosure News: Todd Tillemans Named New CEOhttps://modernaesthetics.com/news/cynosure-news-todd-tillemans-named-new-ceo/2472869/Todd Tillemans is the new Chief Executive Officer of Cynosure, LLC. Mr. Tillemans is the former President of Hershey's flagship U.S. business generating more than $6.5 billion in annual sales. Prior to that, he held various leadership positions across Unilever's
- Revance Shares Positive Efficacy and Duration Data for RT002https://modernaesthetics.com/news/revance-share-positive-efficacy-and-duration-data-for-rt002/2471986/Revance Therapeutics, Inc.'s long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term s
- Special Report: Behind Allergan's and Bonti's Headline-Making Dealhttps://modernaesthetics.com/news/special-report-behind-allergans-and-bontis-headline-making-deal/2472032/The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins— Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001—were coming down the pike. Industry watchers were abuzz with predictions about which toxin
- FDA Says No to Evolus' Botox Rivalhttps://modernaesthetics.com/news/fda-says-no-to-evolus-botox-rival/2472089/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more
- Sciton Launches diVa® Center of Excellence Programhttps://modernaesthetics.com/news/sciton-launches-diva-center-of-excellence-program/2472230/Sciton, Inc.’s new diVa® Center of Excellence Program will spotlight urogynecologists, urologists, OB/GYN's and gynecologists who are dedicated to creating an optimal Treatment Experience for women. The Centers will review data and outcome
- ASAPS: Americans Spent Big on Cosmetic Surgery in 2016https://modernaesthetics.com/news/asaps-americans-spent-big-on-cosmetic-surgery-in-2016/2472257/15 + B That’s the amount of money that Americans doled out for cosmetic surgery in 2016, according to newly released statistics from the American Society for Aesthetic Plastic Surgery (ASAPS). That’s 1.5 B more then they spe
- In a Week of Surprising Acquisitions, Will Syneron Be Next?https://modernaesthetics.com/news/in-a-week-of-surprising-acquisitions-will-syneron-be-next/2472276/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- Merz On The Move: Reflections On Fiscal Year 2015/16https://modernaesthetics.com/news/merz-on-the-move-reflections-on-fiscal-year-201516/2472311/Merz Pharma’s core business has grown by 8.9 percent from EUR 809.8 million to EUR 881.9 million in fiscal 2015/16, the company reports. The company’s total revenue of EUR 1,092.9 million has declined by 5.5 percent compared to previous year
- Study: Lumenato Boosts Skin Barrier Function, Collagen and Ceramideshttps://modernaesthetics.com/news/study-lumenato-boosts-skin-barrier-function-collagen-and-ceramides/2473526/Lycored's Lumenato may improve the skin barrier function and boost collagen and ceramides after 12 weeks of daily supple